| |
All patients (N=286791) |
Lifestyle changes (N=69924) |
Oral monotherapy (N=101749) |
Oral combined (N=64313) |
Oral + Insulin (N=29095) |
Insulin monotherapy (N=21710) |
| Age ( years) mean (SD) |
68.2 (11.4) |
67.5 (12.2) |
68.1 (11.4) |
68.2 (10.6) |
68.7 (10.4) |
70.2 (11.9) |
| Sex, (% of males) |
53.7 |
54.2 |
55.0 |
54.8 |
46.6 |
52.3 |
| Diabetes duration, mean years (SD) |
6.5 (5.1) |
5.03 (3.97) |
5.63 (4.14) |
7.58 (4.99) |
9.30 (6.47) |
8.86 (6.86) |
| HbA1c, % mean (SD)a |
7.1 (1.5) |
6.3 (1.0) |
6.9 (1.3) |
7.6 (1.5) |
8.1 (1.6) |
7.9 (1.7) |
| HbA1c, mmol/mol, mean (SD)a |
54.6 ± 16.0 |
45.7 ± 11.0 |
52.1 ± 14.0 |
59.4 ± 16.1 |
65.4 ± 17.0 |
62.7 ± 18.5 |
| HbA1c ≤ 7% (≤ 53 mmol/mol) (%)a |
56.1 |
85.4 |
63.7 |
40.1 |
24.3 |
32.9 |
| BMI (Kg/m2), mean (SD)b |
29.6 (5.0) |
29.4 (4.8) |
29.6 (4.9) |
29.6 (5.0) |
30.6 (5.3) |
28.7 (5.1) |
| Obesity (BMI≥30 kg/m2) (%)b |
45.4 |
43.8 |
45.5 |
45.2 |
53.4 |
38.3 |
| Current Smoker |
15.6 |
16.8 |
16.3 |
15.0 |
12.6 |
15.2 |
| Any Macrovascular |
17.4 |
13.5 |
16.7 |
18.2 |
27.1 |
30.9 |
| Coronary % |
11.9 |
8,1 |
10.2 |
11.1 |
17.1 |
19.0 |
| Cerebrovascular % |
6.7 |
5.0 |
6.1 |
6.0 |
9.3 |
11.5 |
| Retinopathy % |
5.8 |
1.5 |
2.7 |
6.3 |
17.8 |
17.0 |
| Nephropathyc% |
16.7 |
11.3 |
14.3 |
17.7 |
25.2 |
28.6 |
Renal functiond %
eGFR ≥ 60 mL/min/1.73 m2, %
eGFR 30-59 mL/min/1.73 m2, %
eGFR <30 mL/min/1.73 m2, % |
81.6
17.1
1.3 |
83.7
15.2
1.1 |
83.9
15.4
0.7 |
83.4
16.0
0.6 |
76.7
21.7
1.5 |
63.7
29.4
6.8 |
aN=214,867 patients with at least one HbA1c measurement. b202,451 with body mass index (BMI) available cMicroalbuminuria or macroalbuminuria,
dN= 202,938 with plasma creatinine available for calculating estimated glomerular filtration rate (eGFR) |
